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Introduction {#ner12384-sec-0005}
============

The financial costs of cancer care are a burden to cancer patients, their families, and society as a whole. National cancer care expenditures have been steadily increasing in the United States and are likely to continue to increase as new, more advanced, and often more expensive treatments are adopted as standards of care. The National Cancer Institute calculated the costs for cancer care in the United States in 2010 to be \$125 billion [1](#ner12384-bib-0001){ref-type="ref"}. The economic costs of cancer pain are also substantial. In a Swedish study, mean annual costs per patient were 38% higher for patients with cancer pain (€10,400) compared with patients with chronic non‐cancer pain (€6400) [2](#ner12384-bib-0002){ref-type="ref"}. Abernethy et al. calculated intervention costs from direct medical resource utilization and unit costs based on a model using a population of 100,000 individuals with demographics similar to the U.S. population [3](#ner12384-bib-0003){ref-type="ref"}. The cost for treatment of cancer‐related pain was USD \$579 for guideline‐based care, \$466 for oncology‐based care, and \$315 for usual care, which translates to costs of \$118,436, \$95,300, and \$64,540 per 100,000 population, respectively [3](#ner12384-bib-0003){ref-type="ref"}.

The majority of cancer patients experience pain during the course of their disease and treatment, and approximately 25% of cancer patients die in pain [4](#ner12384-bib-0004){ref-type="ref"}. Although the number of surviving cancer patients in the United States is increasing and expected to reach 18.1 million by 2020, many cancer survivors have multiple, persistent symptoms, including fatigue, distress, pain, and cognitive impairment, which result in a decreased quality of life [5](#ner12384-bib-0005){ref-type="ref"}, [6](#ner12384-bib-0006){ref-type="ref"}, [7](#ner12384-bib-0007){ref-type="ref"}. Symptoms related to cancer and/or its treatment were reported in 92% of survivors one year after diagnosis [7](#ner12384-bib-0007){ref-type="ref"}. More than 25% of cancer survivors have high symptom burden, with pain, fatigue, and depression having the greatest impact on health‐related quality of life (*p* \< 0.0001) [7](#ner12384-bib-0007){ref-type="ref"}. Additionally, cancer patients with high levels of pain (\>3 on a visual analog scale \[VAS\] linked to a 0--10 cm numeric scale) have statistically significantly fewer months of survival than cancer patients with low pain levels (≤3 on VAS) (*p* = 0.002) [8](#ner12384-bib-0008){ref-type="ref"}.

Purpose {#ner12384-sec-0006}
=======

With U.S. health care reform under way, there is increased scrutiny to demonstrate the most clinically‐effective and cost‐effective ways to treat cancer patients. This is especially relevant in the United States given that nearly 20% of gross domestic product is spent on health care. The goal of this analysis was to use administrative claims data which provide details of real‐world patterns of care for individuals based on claims submitted for payment by health care providers, to compare health services utilization and payments in cancer patients who received an intrathecal drug delivery (IDD) system, consisting of a pump and catheter, vs. conventional medical management (CMM) for the treatment of cancer pain.

Patients and Methods {#ner12384-sec-0007}
====================

Data Source {#ner12384-sec-0008}
-----------

We utilized proprietary U.S. health care information provided in the MarketScan^®^ Commercial Claims and Encounters Database from Truven Health Analytics (Ann Arbor, MI). This data base contains de‐identified, person‐specific insurance enrollment/plan benefit data and health data for fully adjudicated and paid claims, including clinical utilization, expenditures, inpatient care, outpatient care, and outpatient prescriptions. The data base covers 31--45 million individuals annually between 2006 and 2010 and includes private sector health data from approximately 100 payers. These data can be linked to track detailed patient information across sites and types of providers and over time.

Study Population Selection {#ner12384-sec-0009}
--------------------------

### IDD Patients {#ner12384-sec-0010}

Patients with an inpatient or outpatient claim for an IDD system (CPT: 62362) implanted between July 1, 2006 and September 30, 2010 were identified. Patients were also required to have a diagnosis for cancer (ICD‐9‐CM: 140.xx‐209.xx, 230.xx‐234.xx, 235.xx‐239.xx) coded in any position on the pump implant claim. Additionally, a minimum of six months of pharmacy data were required. Finally, patients had to be continuously enrolled in their health plan for a minimum of six months before and two months after their IDD system implant. Patients were excluded if they: 1) did not meet the inclusion criteria or 2) had a history of IDD based on pump programming, analysis, refill, or removal codes (CPT: 95990, 95991, 62367, 62368, 62355, 62365) occurring prior to implant.

### CMM Patients {#ner12384-sec-0011}

Patients with an inpatient hospital claim including a diagnosis of cancer coded in any position on the claim (ICD‐9‐CM: 140.xx‐209.xx, 230.xx‐234.xx, 235.xx‐239.xx) between July 1, 2006 and September 30, 2010 were identified. The hospital claim also had to include at least two additional diagnosis codes for symptoms associated with uncontrolled cancer pain or chronic opioid use. These included nausea and/or vomiting (ICD‐9‐CM 787.01--787.03), anorexia (783.0), cachexia (799.4), somnolence (780.09), constipation (564.0), fecal impaction (560.32), bowel obstruction (560.9), or decreased mental status (780.97). The patient also had to fill at least one prescription for an opioid in the six months prior to their hospitalization. Finally, patients had to be continuously enrolled in their health plan for a minimum of six months before and two months after their hospitalization. Patients were excluded if they: 1) did not meet the inclusion criteria, or 2) had any evidence of IDD during the entire analysis period (CPT: 62350, 62351, 62361, 62362, 62355, 62365, 62367, 62368, 95990, 95991).

### Matching {#ner12384-sec-0012}

Patients who receive IDD might be selected for treatment due to patient or physician characteristics that are markedly different from patients receiving CMM. To control for this potential selection bias in claims data, IDD and CMM patients were matched 1:1 based on the Mayo Clinic propensity score matching technique [9](#ner12384-bib-0009){ref-type="ref"}. Approximating randomization, the propensity score matching technique provides an unbiased estimate of the effect of treatment by matching patient characteristics. In this case, the technique removed observed differences in the characteristics of patients who received IDD vs. CMM. The propensity score is the predicted probability, ranging from 0 to 1, of belonging to either the IDD group or the CMM group. To obtain the score, a logistic, stepwise regression was conducted to achieve parsimony and best model fit. The *p*‐value cut‐off for an independent variable\'s entry into the regression was *p* = 0.10. The matching logic used a nearest neighbor greedy algorithm, in which the maximum distance between scores for a matched pair was set at 0.01. The groups were compared pre‐ and post‐match using test statistics appropriate to the underlying data distribution (Student\'s t, chi‐square). A two‐tailed *p* value = 0.05 was used as a cut‐off for statistical significance. All programming was completed using SAS^®^ 9.2 (Cary, NC).

Statistical Analysis {#ner12384-sec-0013}
--------------------

### Timeframe {#ner12384-sec-0014}

The first pump claim between 7/1/06 and 9/30/10 was designated as the index date for IDD patients. The first hospitalization between July 1, 2006 and September 30, 2010 was designated as the index date for CMM patients. The claims data in the six‐month period prior to the index date (as early as January 1, 2006) were used to characterize demographics, comorbidities, and other health services utilization and payments. The costs were recorded in U.S. dollars in the years the services were incurred, without adjustments for inflation. The claims data in the period 2, 6, and 12 months following the index date was used to compare utilization and payments after propensity score matching. Survival data were not available in the claims data base. As a result, only patients continuously enrolled at the follow‐up point (2, 6, and 12 months) were included in the analysis for the follow‐up point, respectively. To insure the two groups remained similar despite attrition over the follow‐up period, the patient characteristics in the six months prior to index were retested by group with the remaining sample at 6 and 12 months.

Baseline Period {#ner12384-sec-0015}
---------------

In the six‐month period prior to index, a series of variables was created a priori for consideration in the matching procedure based on the assumption that they would either be predictive of receiving IDD or predictive of an outcome of interest (e.g., health services utilization or payments). Between‐group differences were compared using descriptive statistics and bivariate tests appropriate to the underlying data distribution. These included: age, gender, region, health plan type, year of index date, baseline utilization, baseline payment, type of cancer, presence of multiple cancers, metastatic cancer, Charlson Comorbidity Index score, treatment by oncologist, treatment by pain specialist, prescription drug use (opioids/tramadol, psychostimulants, laxatives, appetite enhancers, corticosteroids, anticonvulsants, antidepressants, antiemetics, anxiolytics), tumor ablation by approach (i.e., endoscopic, external, open, percutaneous), biopsy by approach, tumor destruction by approach, tumor excision by approach, tumor resection by approach, radiation therapy and chemotherapy.

Follow‐Up Period {#ner12384-sec-0016}
----------------

Health services utilization and payments for the matched pairs of IDD and CMM patients were compared at 2, 6, and 12 months following the index date. Group differences were compared using descriptive statistics and bivariate tests appropriate to matched samples and to the underlying data distribution (Wilcoxon signed‐rank for nonparametric continuous variables).

Results {#ner12384-sec-0017}
=======

Patient Population {#ner12384-sec-0018}
------------------

### IDD Patients {#ner12384-sec-0019}

Of the 3625 patients who received their first implanted IDD system between July 1, 2006 and September 30, 2010, 281 (8%) had cancer. Of those, 182 (64.8%) were continuously enrolled in their health plan for a minimum of six months before and two months after their index date. Of the 182 patients, 143 (78.6%) had pharmacy claims data available, as some payers do not submit their pharmacy claims to the MarketScan data base. One patient appearing in both treatment groups was deleted. Therefore, 142 IDD patients comprised the IDD sample before matching.

### CMM Patients {#ner12384-sec-0020}

There were 13,137 patients hospitalized between July 1, 2006 and September 30, 2010 with a diagnosis code of cancer and at least two additional codes associated with uncontrolled pain or chronic opioid use. Of these, 8381 (63.8%) were continuously enrolled in their health plan for a minimum of six months before and two months after their index date. Of these, 5982 (71.4%) had pharmacy claims data available for the six‐month baseline period. Of these, 32 (0.5%) had evidence of IDD in the six months prior to index and were deleted. Of the remaining 5950 patients, 3188 (53.6%) had at least one opioid prescription at baseline. Therefore, 3188 patients comprised the CMM sample before matching.

### Pre‐ and Post‐Match Baseline Characteristics {#ner12384-sec-0021}

The propensity score match revealed several patient characteristics that were statistically significantly different between the IDD and CMM groups prior to index, suggesting the patients who received IDD represented a different subset of cancer pain patients compared with patients who received CMM (Table [1](#ner12384-tbl-0001){ref-type="table-wrap"}). To illustrate, patients with IDD had a higher average number of hospitalizations, more days in hospital, more cases of metastatic disease and multiple cancers, and were more likely to have visited a pain specialist.

###### 

Patient Characteristics Six Months Prior to Index: Pre‐ and Post‐Match.

  Characteristic                                                          Pre‐match CMM (*N* = 3188)   Pre‐match IDD (*N* = 142)   Pre‐match *p* value[\*](#ner12384-note-0002){ref-type="fn"}   Post‐match *p* value[\*](#ner12384-note-0002){ref-type="fn"} (*n* = 73 pairs)   
  ----------------------------------------------------------------------- ---------------------------- --------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------
  Age                                                                     Mean                         51.55                       51.92                                                         0.6755                                                                          0.7552
  Emergency room visits[†](#ner12384-note-0003){ref-type="fn"}            Mean                         0.96                        1.42                                                          0.01[‡](#ner12384-note-0004){ref-type="fn"}                                     0.5266
  Inpatient hospital visits[†](#ner12384-note-0003){ref-type="fn"}        Mean                         0.25                        1.13                                                          \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.9125
  Outpatient hospital visits                                              Mean                         9.36                        13.55                                                         \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.1171
  Physician office visits                                                 Mean                         14.31                       18.97                                                         \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.1739
  Days in hospital[†](#ner12384-note-0003){ref-type="fn"}                 Mean                         1.18                        7.35                                                          \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.7954
  Total payments[†](#ner12384-note-0003){ref-type="fn"}                   Mean                         38409.7                     77393.3                                                       \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.7711
  Home health visits                                                      Mean                         1.07                        3.62                                                          \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.0400[‡](#ner12384-note-0004){ref-type="fn"}
  Hospice days                                                            Mean                         0.04                        0.43                                                          0.0024[‡](#ner12384-note-0004){ref-type="fn"}                                   0.1566
  Laboratory services                                                     Mean                         1.43                        1.55                                                          0.6416                                                                          0.0204[‡](#ner12384-note-0004){ref-type="fn"}
  Gender                                                                                                                                                                                                                                                                         
  Males                                                                   N                            1168                        55                                                            0.6124                                                                          0.2038
  Females                                                                 N                            2020                        87                                                                                                                                            
  Year of index date                                                                                                                                                                                                                                                             
  2006                                                                    N                            302                         19                                                            0.0286[‡](#ner12384-note-0004){ref-type="fn"}                                   0.0176[‡](#ner12384-note-0004){ref-type="fn"}
  2007                                                                    N                            607                         32                                                                                                                                            
  2008                                                                    N                            741                         31                                                                                                                                            
  2009                                                                    N                            852                         44                                                                                                                                            
  2010[†](#ner12384-note-0003){ref-type="fn"}                             N                            686                         16                                                                                                                                            
  Health plan type                                                                                                                                                                                                                                                               
  Comprehensive                                                           N                            158                         8                                                             0.3265                                                                          0.5173
  Exclusive provider organization                                         N                            29                          0                                                                                                                                             
  Health maintenance organization                                         N                            546                         23                                                                                                                                            
  Place of service                                                        N                            226                         11                                                                                                                                            
  Preferred provider organization                                         N                            1994                        82                                                                                                                                            
  Place of service with capitation                                        N                            16                          1                                                                                                                                             
  Consumer‐directed health plan                                           N                            80                          5                                                                                                                                             
  High‐deductible health plan                                             N                            21                          3                                                                                                                                             
  Unknown                                                                 N                            118                         9                                                                                                                                             
  Region[†](#ner12384-note-0003){ref-type="fn"}                                                                                                                                                                                                                                  
  Northeast                                                               N                            239                         10                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.2989
  North Central                                                           N                            892                         55                                                                                                                                            
  South                                                                   N                            1574                        39                                                                                                                                            
  West                                                                    N                            476                         38                                                                                                                                            
  Unknown                                                                 N                            7                           0                                                                                                                                             
  Multiple cancers[†](#ner12384-note-0003){ref-type="fn"}                                                                                                                                                                                                                        
  No                                                                      N                            1177                        12                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.7852
  Yes                                                                     N                            2011                        130                                                                                                                                           
  Any diabetes prescription[§](#ner12384-note-0005){ref-type="fn"}        Sum                          380                         18                                                            0.7857                                                                          0.0706
  Antihypertensive use[§](#ner12384-note-0005){ref-type="fn"}             Sum                          1001                        42                                                            0.6470                                                                          0.4761
  Tumor ablation, endoscopic[\#](#ner12384-note-0006){ref-type="fn"}      Sum                          10                          2                                                             0.0332[‡](#ner12384-note-0004){ref-type="fn"}                                   0.5596
  Tumor ablation, external                                                Sum                          0                           0                                                             NA                                                                              NA
  Tumor ablation, open                                                    Sum                          0                           0                                                             NA                                                                              NA
  Tumor ablation, percutaneous                                            Sum                          4                           0                                                             0.6728                                                                          0.3156
  Tumor ablation, percutaneous endoscopic                                 Sum                          0                           0                                                             NA                                                                              NA
  Tumor ablation via body                                                 Sum                          2                           0                                                             0.7653                                                                          NA
  Anticonvulsant use[†](#ner12384-note-0003){ref-type="fn"}               Sum                          358                         44                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.1313
  Antidepressant use                                                      Sum                          1013                        64                                                            0.0009[‡](#ner12384-note-0004){ref-type="fn"}                                   0.0325[‡](#ner12384-note-0004){ref-type="fn"}
  Antiemetic use[†](#ner12384-note-0003){ref-type="fn"}                   Sum                          1603                        83                                                            0.0568                                                                          0.7400
  Anxiolytic use                                                          Sum                          1499                        84                                                            0.0046[‡](#ner12384-note-0004){ref-type="fn"}                                   0.6162
  Biopsy, endoscopic[\#](#ner12384-note-0006){ref-type="fn"} ^,†^         Sum                          699                         17                                                            0.0047[‡](#ner12384-note-0004){ref-type="fn"}                                   0.6552
  Biopsy, external[†](#ner12384-note-0003){ref-type="fn"}                 Sum                          126                         2                                                             0.1229                                                                          1.0000
  Biopsy, open                                                            Sum                          241                         11                                                            0.9343                                                                          0.7539
  Biopsy, percutaneous[†](#ner12384-note-0003){ref-type="fn"}             Sum                          705                         27                                                            0.3828                                                                          1.0000
  Biopsy, percutaneous endoscopic                                         Sum                          23                          2                                                             0.3534                                                                          0.3156
  Biopsy, via body[†](#ner12384-note-0003){ref-type="fn"}                 Sum                          126                         0                                                             0.0157[‡](#ner12384-note-0004){ref-type="fn"}                                   NA
  Chemotherapy                                                            Sum                          1372                        89                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.8685
  Corticosteroid use                                                      Sum                          1111                        56                                                            0.2623                                                                          0.1668
  Tumor destruction, endoscopic[\#](#ner12384-note-0006){ref-type="fn"}   Sum                          0                           0                                                             NA                                                                              NA
  Tumor destruction, open                                                 Sum                          1                           0                                                             0.8328                                                                          NA
  Tumor destruction, via body                                             Sum                          0                           0                                                             NA                                                                              NA
  Appetite enhancer use                                                   Sum                          754                         54                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.2727
  Tumor excision, endoscopic[\#](#ner12384-note-0006){ref-type="fn"}      Sum                          150                         5                                                             0.5123                                                                          0.2452
  Tumor excision, external                                                Sum                          44                          1                                                             0.4949                                                                          0.3156
  Tumor excision, open                                                    Sum                          79                          5                                                             0.4380                                                                          1.0000
  Tumor excision, percutaneous                                            Sum                          8                           0                                                             0.5501                                                                          NA
  Tumor excision, percutaneous endoscopic                                 Sum                          0                           0                                                             NA                                                                              NA
  Tumor excision, via body                                                Sum                          1                           0                                                             0.8328                                                                          NA
  Laxative use                                                            Sum                          226                         4                                                             0.0495[‡](#ner12384-note-0004){ref-type="fn"}                                   0.1722
  Metastatic disease[†](#ner12384-note-0003){ref-type="fn"}               Sum                          1401                        111                                                           \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.5747
  Treated by oncologist[†](#ner12384-note-0003){ref-type="fn"}            Sum                          1089                        72                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.1268
  Opioid/tramadol use                                                     Sum                          3188                        132                                                           \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 NA
  Treated by pain specialist[†](#ner12384-note-0003){ref-type="fn"}       Sum                          88                          27                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 1.0000
  Psychostimulant use                                                     Sum                          81                          6                                                             0.2182                                                                          1.0000
  Radiation therapy                                                       Sum                          651                         52                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.5528
  Tumor resection, open[\#](#ner12384-note-0006){ref-type="fn"}           Sum                          4                           0                                                             0.6728                                                                          NA
  Bone cancer[†](#ner12384-note-0003){ref-type="fn"}                      Sum                          163                         25                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.7714
  Breast cancer[†](#ner12384-note-0003){ref-type="fn"}                    Sum                          568                         31                                                            0.2230                                                                          0.1748
  Carcinoma                                                               Sum                          288                         15                                                            0.5352                                                                          1.0000
  Colorectal cancer                                                       Sum                          436                         23                                                            0.3939                                                                          0.7658
  Digestive system cancer                                                 Sum                          941                         66                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.3548
  Endocrine cancer                                                        Sum                          34                          1                                                             0.6787                                                                          0.6129
  Genitourinary cancer[†](#ner12384-note-0003){ref-type="fn"}             Sum                          432                         27                                                            0.0646                                                                          0.3156
  Kaposi\'s sarcoma                                                       Sum                          4                           1                                                             0.0814                                                                          0.1651
  Lung cancer[†](#ner12384-note-0003){ref-type="fn"}                      Sum                          359                         38                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.4335
  Lymphoma/leukemia                                                       Sum                          1300                        90                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.5060
  Oral cancer                                                             Sum                          204                         3                                                             0.0385[‡](#ner12384-note-0004){ref-type="fn"}                                   1.0000
  Other type of cancer                                                    Sum                          1778                        106                                                           \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.4706
  Pancreatic cancer[†](#ner12384-note-0003){ref-type="fn"}                Sum                          173                         16                                                            0.0032[‡](#ner12384-note-0004){ref-type="fn"}                                   0.5962
  Prostate cancer[†](#ner12384-note-0003){ref-type="fn"}                  Sum                          99                          13                                                            \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.4670
  Respiratory/thoracic cancer                                             Sum                          100                         3                                                             0.4904                                                                          0.1544
  Skin cancer                                                             Sum                          168                         7                                                             0.8589                                                                          0.7308
  Charlson comorbidity Index score components                                                                                                                                                                                                                                    
  Acute myocardial infarction                                             Sum                          14                          0                                                             0.4287                                                                          0.3156
  AIDS                                                                    Sum                          13                          0                                                             0.4458                                                                          NA
  Acute ulcer                                                             Sum                          56                          3                                                             0.7530                                                                          1.0000
  Congestive heart failure                                                Sum                          70                          2                                                             0.5280                                                                          0.4044
  Cirrhosis                                                               Sum                          34                          1                                                             0.6787                                                                          1.0000
  Chronic pulmonary disease                                               Sum                          386                         14                                                            0.4200                                                                          0.5740
  Chronic ulcer                                                           Sum                          14                          1                                                             0.6444                                                                          0.3156
  Cardiovascular disease                                                  Sum                          113                         4                                                             0.6450                                                                          0.4670
  Dementia                                                                Sum                          4                           0                                                             0.6728                                                                          NA
  Diabetes[†](#ner12384-note-0003){ref-type="fn"}                         Sum                          456                         16                                                            0.3101                                                                          0.7852
  Diabetes with sequelae                                                  Sum                          104                         3                                                             0.4472                                                                          0.1544
  Liver disease                                                           Sum                          12                          0                                                             0.4639                                                                          NA
  Myocardial infarction (history)                                         Sum                          22                          1                                                             0.9841                                                                          0.3156
  Plegia (all types)[†](#ner12384-note-0003){ref-type="fn"}               Sum                          6                           3                                                             \<0.0001[‡](#ner12384-note-0004){ref-type="fn"}                                 0.3156
  Peripheral vascular disease                                             Sum                          46                          2                                                             0.9731                                                                          0.3156
  Renal disease                                                           Sum                          111                         2                                                             0.1818                                                                          0.3156
  Rheumatoid arthritis                                                    Sum                          56                          0                                                             0.1112                                                                          0.0801

Statistical test performed appropriate to the variable type and underlying data distribution.

Variable remained in stepwise logistic regression for developing propensity score at *p* \< 0.10 level of significance.

Indicates a statistically significant difference at the *p* \< 0.05 level.

Due to the short six‐month baseline period, use of drugs for diabetes and hypertension, as two common comorbidities, was included to increase our chances of identification of these conditions above and beyond the inclusion of the Charlson Comorbidity Index score components.

Tumor biopsy, excision, resection, destruction, and ablation were categorized based on the level of invasiveness of the approach.

CMM, conventional medical management; IDD, intrathecal drug delivery.

### Propensity Score Match {#ner12384-sec-0022}

Similarly, the distribution of propensity scores was markedly different between the two groups prior to index, depicting how the IDD and CMM patients were characteristically unique and emphasizing the importance of employing a methodology to address for potential selection bias. After matching patients 1:1 using their propensity score, 73 matched pairs (*n* = 146) were retained for further analysis. The average propensity score for the 73 matched IDD patients was 0.1177318. The average propensity score for the 73 matched CMM patients was 0.1177252.

Following the match, with few exceptions, nearly all variables were no longer statistically different between the groups. For those remaining significant differences, the associations were not particularly strong. Therefore, we determined that no further statistical adjustment via regression was required to compare outcomes, and simple bivariate tests were used for post‐index analysis.

### Post‐Match Study Population {#ner12384-sec-0023}

Patient attrition was expected given the diagnosis of cancer. At two months, 73 matched pairs were continuously enrolled and thus included in the analysis. At six months, 50 IDD patients and 39 CMM patients were included in the analysis. At 12 months, 29 IDD patients and 23 CMM patients were included in the analysis. Re‐testing of baseline characteristics by group at 6 and 12 months revealed no significant differences indicating the groups remained similar and follow‐up comparisons were appropriate.

Post‐Match Follow‐Up Outcomes {#ner12384-sec-0024}
-----------------------------

### Medical Utilization {#ner12384-sec-0025}

IDD patients had a significantly lower average number of inpatient hospitalizations (two months, *p* = 0.0010; six months, *p* = 0.0358), outpatient hospital visits (six months, *p* = 0.0133), emergency department visits (two months, *p* \< 0.0001; six months, *p* = 0.0049), and lab services (six months, *p* = 0.0168) compared with CMM patients at all follow‐up times with statistical significance achieved at the time points shown (Fig. [1](#ner12384-fig-0001){ref-type="fig"}). While the number of physician office visits was fewer at two months in the IDD patients, it was slightly higher at 6 and 12 months. Conversely, while the number of home health and hospice visits was higher at two and six months for IDD patients (hospice at two months, *p* = 0.0301), it was fewer at 12 months. IDD patients had an average of one day less in hospital after two months, and 4 days after 12 months, compared with CMM patients.

![Medical utilization by treatment group over 12 months. \* Indicates a statistically significant difference at the *p* \< 0.05 level for the time point(s) listed. No adjustments made for multiple comparisons. CMM, conventional medical management; ED, emergency department; ICU, intensive care unit; IDD, intrathecal drug delivery; IP, inpatient; LOS, length of stay; OP, outpatient.](NER-19-196-g001){#ner12384-fig-0001}

### Pharmacy Utilization {#ner12384-sec-0026}

The IDD group had a lower average number of anxiolytic, antiemetic (two months, *p* = 0.0029; six months, *p* = 0.0130), corticosteroid (two months, *p* = 0.0076) and appetite enhancer prescriptions compared with CMM patients at all follow‐up times with statistical significance achieved at the time points shown (Fig. [2](#ner12384-fig-0002){ref-type="fig"}). However, IDD patients had a higher average number of antidepressant (two months, *p* = 0.0136; six months, *p* = 0.0116), psychostimulant (not significant), and opioid prescriptions (not significant).

![Pharmacy utilization by treatment group over 12 months. \* Indicates a statistically significant difference at the *p* \< 0.05 level for the time point(s) listed. No adjustments made for multiple comparisons. CMM, conventional medical management; ED, emergency department; ICU, intensive care unit; IDD, intrathecal drug delivery; IP, inpatient; LOS, length of stay; OP, outpatient.](NER-19-196-g002){#ner12384-fig-0002}

### Payments {#ner12384-sec-0027}

IDD patients had lower emergency department (two months, *p* \< 0.0001; 12 months, *p* = 0.0076), home health, and lab payments compared with CMM patients at all follow‐up times with statistical significance achieved at time points shown. Although not significantly different, pharmacy payments were consistently higher compared with CMM patients (Table [2](#ner12384-tbl-0002){ref-type="table-wrap"}; Fig. [3](#ner12384-fig-0003){ref-type="fig"}). Payments for inpatient hospitalizations, outpatient hospital visits, and hospice care started out higher for IDD patients, yet were all lower by 12 months (hospice at six months, *p* = 0.0113). Conversely, physician office payments started out lower for IDD patients compared with CMM patients and were higher by 12 months (two months, *p* = 0.0160). Combined medical and total payments (medical + pharmacy + cost of IDD implant) were higher for IDD patients at two months (\$58,209 vs. \$55,157 for CMM), but lower after six months compared with CMM patients (\$97,761 vs. \$103,306, respectively; Fig. [4](#ner12384-fig-0004){ref-type="fig"}). At 12 months, pharmacy costs were \$9264 higher for IDD while medical costs were \$12,459 lower, achieving a total cost savings of \$3195 for IDD relative to CMM. When the costs associated with the index date for both groups were excluded (i.e., cost of IDD system, cost of hospitalization for CMM), the costs associated with IDD were \$7255 lower than with CMM.

![Payments by treatment group over 12 months (U.S. dollars). CMM, conventional medical management; ED, emergency department; IDD, intrathecal drug delivery; IP, inpatient; OP, outpatient.](NER-19-196-g003){#ner12384-fig-0003}

![Contribution of IDD implant to total payments (U.S. dollars). The mean difference in total payments favored CMM at two months (\$55,157 for CMM vs. \$58,209 for IDD), IDD at six months (\$97,761 for IDD vs. \$103,306 for CMM), and IDD at 12 months (\$126,407 IDD vs. \$129,602 for CMM). CMM, conventional medical management; ED, emergency department; IDD, intrathecal drug delivery; IP, inpatient; OP, outpatient.](NER-19-196-g004){#ner12384-fig-0004}

###### 

Payments by Treatment Group Over 12 Months (U.S. Dollars).

  Payment type           Month   *N*         Intrathecal drug delivery (IDD)   Conventional medical management (CMM)   Mean difference IDD‐CMM   *t*‐test *p* value[\*](#ner12384-note-0008){ref-type="fn"}                                                                            
  ---------------------- ------- ----------- --------------------------------- --------------------------------------- ------------------------- ------------------------------------------------------------ ---------- ------------ ------------------------------------------------ --------------------------------------------------
  Inpatient hospital     2       73/73       \$36,779                          \$10,479                                \$104,790                 \$35,033                                                     \$23,136   \$38,332     \$1746                                           0.8938
  6                      50/39   \$47,692    \$15,614                          \$128,009                               \$41,251                  \$28,163                                                     \$39,985   \$6441       0.7629                                           
  12                     29/23   \$40,218    \$23,372                          \$48,300                                \$44,341                  \$34,321                                                     \$34,420   (\$4123)     0.7312                                           
  Emergency department   2       73/73       \$300                             \$0                                     \$660                     \$1152                                                       \$622      \$1550       (\$852)                                          \<0.0001[\*](#ner12384-note-0008){ref-type="fn"}
  6                      50/39   \$664       \$0                               \$1684                                  \$1511                    \$732                                                        \$2371     (\$847)      0.0521                                           
  12                     29/23   \$584       \$148                             \$1133                                  \$2486                    \$1416                                                       \$3466     (\$1902)     0.0076[\*](#ner12384-note-0008){ref-type="fn"}   
  Outpatient hospital    2       73/73       \$13,163                          \$6772                                  \$15,194                  \$8884                                                       \$2124     \$13,527     \$4279                                           0.0744
  6                      50/39   \$24,499    \$16,091                          \$28,616                                \$30,097                  \$10,981                                                     \$40,856   (\$5598)     0.4497                                           
  12                     29/23   \$41,037    \$28,911                          \$43,574                                \$47,181                  \$14,493                                                     \$67,531   (\$6144)     0.6929                                           
  Physician office       2       73/73       \$3726                            \$1184                                  \$6722                    \$7260                                                       \$1549     \$10,407     (\$3534)                                         0.0160[\*](#ner12384-note-0008){ref-type="fn"}
  6                      50/39   \$13,829    \$4770                            \$20,491                                \$21,164                  \$2149                                                       \$31,501   (\$7335)     0.1881                                           
  12                     29/23   \$27,004    \$5040                            \$38,662                                \$25,050                  \$3664                                                       \$45,984   \$1954       0.8685                                           
  Lab                    2       73/73       \$77                              \$0                                     \$450                     \$139                                                        \$0        \$528        (\$62)                                           0.4473
  6                      50/39   \$122       \$0                               \$542                                   \$124                     \$0                                                          \$294      (\$2)        0.9892                                           
  12                     29/23   \$112       \$0                               \$420                                   \$123                     \$0                                                          \$290      (\$11)       0.9192                                           
  Home health            2       73/73       \$605                             \$0                                     \$1374                    \$715                                                        \$0        \$1899       (\$110)                                          0.6868
  6                      50/39   \$1784      \$508                             \$5781                                  \$4701                    \$0                                                          \$19,815   (\$2917)     0.3250                                           
  12                     29/23   \$3092      \$507                             \$9243                                  \$4182                    \$587                                                        \$9967     (\$1090)     0.6850                                           
  Hospice                2       73/73       \$926                             \$0                                     \$3982                    \$232                                                        \$0        \$1259       \$694                                            0.1573
  6                      50/39   \$2179      \$0                               \$5222                                  \$12                      \$0                                                          \$76       \$2167       0.0113[\*](#ner12384-note-0008){ref-type="fn"}   
  12                     29/23   \$376       \$0                               \$1388                                  \$1121                    \$0                                                          \$3587     (\$745)      0.3089                                           
  Other misc.            2       73/73       \$770                             \$0                                     \$3397                    \$434                                                        \$0        \$1833       \$336                                            0.4588
  6                      50/39   \$1092      \$0                               \$6014                                  \$344                     \$0                                                          \$763      \$748        0.4424                                           
  12                     29/23   \$315       \$0                               \$768                                   \$713                     \$0                                                          \$1353     (\$398)      0.1870                                           
  Medical subtotal       2       73/73       \$56,346                          \$34,481                                \$106,518                 \$53,849                                                     \$43,907   \$38,530     \$2497                                           0.8509
  6                      50/39   \$91,863    \$63,900                          \$129,831                               \$99,204                  \$84,203                                                     \$71,314   (\$7341)     0.7516                                           
  12                     29/23   \$112,739   \$91,331                          \$91,548                                \$125,198                 \$119,840                                                    \$73,165   (\$12,459)   0.5974                                           
  Pharmacy               2       73/73       \$1863                            \$889                                   \$2401                    \$1308                                                       \$611      \$1767       \$555                                            0.1138
  6                      50/39   \$5898      \$2537                            \$9296                                  \$4102                    \$1875                                                       \$7955     \$1796       0.3385                                           
  12                     29/23   \$13,668    \$4116                            \$24,232                                \$4404                    \$2551                                                       \$5791     \$9264       0.0795                                           
  Total                  2       73/73       \$58,209                          \$35,370                                                          \$55,157                                                     \$44,518                \$3052                                           0.8181
  6                      50/39   \$97,761    \$66,437                                                                  \$103,306                 \$86,078                                                                (\$5545)     0.8107                                           
  12                     29/23   \$126,407   \$95,447                                                                  \$129,602                 \$122,391                                                               (\$3195)     0.8979                                           

Indicates a statistically significant difference at the *p* \< 0.05 level for the time point(s) listed. No adjustments made for multiple comparisons.

Discussion {#ner12384-sec-0028}
==========

Recent practice guidelines have emphasized concern over the socioeconomic costs of potential complications and anxieties associated with screening and subsequent interventions. Most prominently, this has involved prostate‐specific antigen screening and therapeutic alternatives, such as watchful waiting, in subgroups of prostate cancer patients, and low‐dose CT screening for lung cancer in at‐risk patients. Such preventive efforts are increasingly being scrutinized on the basis of cost as well as efficacy. Indeed, in May 2014 the Medicare Evidence & Coverage Advisory Committee recommended against coverage for annual lung cancer screening in at‐risk persons, although screening had been endorsed by more than 40 medical societies and a surgical cure of stage 1 lung cancer is often possible [10](#ner12384-bib-0010){ref-type="ref"}. With the increased influence of health care economics and outcomes research, futile care at the end of life, which consumes 25% of the entire Medicare budget, is also a target for cost cutting. The budget sequester included a 2% across‐the board reduction in Medicare spending in 2013, and during the past five years health care spending in the U.S. has grown at historically low rates (3.6--4.1% annually) [11](#ner12384-bib-0011){ref-type="ref"}. Further cuts are inevitable. Advocacy of a costly intervention to palliate cancer pain, often at the end of life, must therefore be justified on the basis of ethics to relieve suffering, and efficacy that is superior to CMM.

The cost of IDD vs. CMM for cancer pain management depends, as is shown in this study, on the length of observed follow‐up where, in this analysis, continuous enrollment was used as a proxy for survival. Thus, patient selection is critical in order for interventional cancer pain management to be cost effective, and is highly dependent on physician judgment of prognostic factors that determine length of survival. We were cognizant that the number of IDD recipients in the cancer pain population would be small, and that sample size would drop over time due, in part, to length of survival.

The literature on the use of IDD in cancer pain includes a selection of case series, best practices consensus guidelines, and two randomized controlled trials [4](#ner12384-bib-0004){ref-type="ref"}, [12](#ner12384-bib-0012){ref-type="ref"}, [13](#ner12384-bib-0013){ref-type="ref"}, [14](#ner12384-bib-0014){ref-type="ref"}, [15](#ner12384-bib-0015){ref-type="ref"}. In the randomized trial by Smith and colleagues, IDD patients had statistically significantly lower toxicity scores (50% reduction) compared to patients receiving conventional treatment (e.g., systemic opioids) for pain management (17% reduction, *p* = 0.004). IDD also lowered pain scores by 52% vs. 39% in the CMM group (*p* = 0.055) [14](#ner12384-bib-0014){ref-type="ref"}.

While the existing studies focus on the clinical and quality‐of‐life benefits of IDD, it is important to explore whether IDD provides economic benefits, in terms of lower direct costs to payers, or potential indirect cost benefits, such as fewer readmissions or fewer days in hospital for patients. Consequently, this retrospective claims analysis compared health services utilization and payments, from a payer perspective, in patients with cancer receiving either IDD or CMM for the management of cancer‐related pain.

The use of propensity score matching was deemed appropriate to address potential selection bias, as IDD patients might be systematically different from CMM patients. Indeed, the distribution of characteristics prior to index and propensity scores demonstrated that across multiple dimensions the two patient groups were disparate. For example, IDD patients had more metastatic disease, were more likely to visit a pain specialist, and were more likely to have a hospitalization and longer length of stay during the baseline period. After propensity score matching, however, the two groups were very similar with scores within 0.01 for a pair of characteristics. The use of simple bivariate statistics to test associations was reasonable, given that the few variables that remained significant after matching were unlikely to affect key outcomes including hospitalization, length of stay, and total medical costs.

Over the 12‐month follow‐up, IDD patients had lower medical utilization and lower total medical payments, driven by the savings in hospitals and emergency departments. The nonsignificant differences might have been affected by lack of power to detect a difference given the small sample. However, IDD patients had higher use of certain classes of medications, such as opioids and antidepressants, and total pharmacy payments were higher compared with CMM patients.

Limitations {#ner12384-sec-0029}
-----------

Administrative claims data bases are developed for the purpose of payment. Moreover, utilization and payments are only reflective of what was coded, with the assumption that most coding is accurate and complete. Additionally, claims data cannot capture over‐the‐counter utilization of medications or adherence to therapy. For the cancer population specifically, claims data do not include measures of severity, such as tumor staging or quality‐of‐life information. Given the advanced clinical condition for many cancer pain patients, especially those who receive IDD, we observed a measurable decline in enrollment status post‐index. We were unable to discern whether patients no longer were enrolled in their health plan or died, unless they died in hospital. The small sample size likely affected our ability to detect statistically significant differences between treatment groups despite apparent trends. In terms of the analytical approach, the use of propensity score matching can only control for observed differences between treatment groups; unknown or unobserved confounding may still exist. While the use of instrumental variables could have addressed this limitation, the identification of an appropriate instrumental variable for this patient population is challenging. Finally, these findings are only generalizable to other U.S. commercially insured populations and not to Medicare or Medicaid patients.

Conclusion {#ner12384-sec-0030}
==========

Despite the high initial cost of IDD, this retrospective analysis of cancer pain patients suggests that patients with IDD incur lower medical utilization and payments over the first year post‐implant compared with CMM. Total average payments for IDD were \$3195 lower per patient than for CMM. Future research with a larger, longitudinal sample and with patient‐reported outcomes, including pain severity and quality of life, would contribute to health economics and outcomes research, and assist with future guideline development.
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